Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 387Skin Neoplasms 91Carcinoma, Non-Small-Cell Lung 78Breast Neoplasms 56Neoplasms 55Colorectal Neoplasms 52Lung Neoplasms 51Neoplasm Metastasis 46Ovarian Neoplasms 44Lymphoma, T-Cell, Cutaneous 44Carcinoma, Renal Cell 43Squamous Cell Carcinoma of Head and Neck 42Uveal Melanoma 39Pancreatic Neoplasms 37Sarcoma 36Carcinoma, Basal Cell 36Head and Neck Neoplasms 33Uterine Cervical Neoplasms 32Prostatic Neoplasms 32Stomach Neoplasms 30Carcinoma, Hepatocellular 30Endometrial Neoplasms 29Carcinoma, Merkel Cell 29Urinary Bladder Neoplasms 28Kidney Neoplasms 26Triple Negative Breast Neoplasms 24Carcinoma, Squamous Cell 23Esophageal Neoplasms 22Lymphoma 21Mycosis Fungoides 19

Interventions

diphenylcyclopropenone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cutaneous Metastases × Dermatologic × Clear all
NCT05481658 2026-02-10

Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
100 enrolled
Dermatologic

Cutaneous Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡